MIM
COGT icon

Monashee Investment Management’s Cogent Biosciences COGT Stock Holding History

Monashee Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,000
Closed -$592K – 79
2023
Q2 		$592K Buy
+50,000
New +$574K 0.14% 64
2018
Q2 		– Sell
-43,750
Closed -$1.94M – 167
2018
Q1 		$1.94M Buy
+43,750
New +$1.94M 0.54% 55

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Monashee Investment Management's COGT Position: Q3 2023 in Review

Monashee Investment Management sold out of Cogent Biosciences (COGT) in Q3 2023, closing a stake of 50,000 shares — an estimated $592K sold.

Monashee Investment Management first reported a position in COGT in Q1 2018 and held it in 2 quarters. The position peaked at $1.94M in Q1 2018. 135 funds tracked by Wall St. Rank hold COGT as of Q3 2023.

  • Monashee Investment Management reported no remaining Cogent Biosciences position as of Q3 2023 after selling out during the quarter.
  • Monashee Investment Management sold 50,000 Cogent Biosciences shares in Q3 2023, an estimated $592K.
  • Monashee Investment Management first reported a position in Cogent Biosciences in Q1 2018 and held it in 2 quarters.
  • Monashee Investment Management's Cogent Biosciences position peaked at $1.94M in Q1 2018.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2023.

Based on Monashee Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.